APO Research
Talk to an analyst

APO RESEARCH · REPORT

IBS Treatment

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global IBS Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025191 pages

Choose your research edition.

Industry ResearchIBS Treatment Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal IBS Treatment Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal IBS Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IBS Treatment Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal IBS Treatment Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global IBS Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for IBS Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for IBS Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for IBS Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for IBS Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of IBS Treatment include Takeda Pharmaceutical Company (Japan), Nestle (Switzerland), Novartis (Switzerland), Pfizer (U.S.), Synthetic Biologics (U.S.), Synergy Pharmaceuticals (U.S.), Sucampo Pharmaceuticals (U.S.), Sebela Pharmaceuticals (Ireland) and RedHill Biopharma (Israel), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global IBS Treatment market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of IBS Treatment and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents IBS Treatment revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the IBS Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

IBS Treatment Segment by Company

Takeda Pharmaceutical Company (Japan)

Nestle (Switzerland)

Novartis (Switzerland)

Pfizer (U.S.)

Synthetic Biologics (U.S.)

Synergy Pharmaceuticals (U.S.)

Sucampo Pharmaceuticals (U.S.)

Sebela Pharmaceuticals (Ireland)

RedHill Biopharma (Israel)

Protagonist Therapeutics (U.S.)

Probi (Sweden)

Lexicon Pharmaceuticals (U.S.)

Ironwood Pharmaceuticals (U.S.)

Ipsen (France)

Innovate Biopharmaceuticals (U.S.)

Bausch Health

AstraZeneca (U.K)

Astellas Pharma (Japan)

Ardelyx (U.S.)

Allergan (Ireland)

Alfasigma USA (Italy)

Abbott Laboratories (U.S.)

IBS Treatment Segment by Type

IBS-D

IBS-C

IBS-M

IBS Treatment Segment by Application

Hospitals

Clinics

Research Laboratories

IBS Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IBS Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IBS Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IBS Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of IBS Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global IBS Treatment industry.

Chapter 3: Detailed analysis of IBS Treatment companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, IBS Treatmentrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global IBS Treatment Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of IBS-D Table 3. Key Players of IBS-C Table 4. Key Players of IBS-M Table 4. Global IBS Treatment Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Hospitals Table 6. Key Players of Clinics Table 7. Key Players of Research Laboratories Table 8. Global IBS Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global IBS Treatment Market Size by Region (2021-2026) & (US$ Million) Table 10. Global IBS Treatment Market Share by Region (2021-2026) Table 11. Global IBS Treatment Market Size by Region (2027-2032) & (US$ Million) Table 12. Global IBS Treatment Market Share by Region (2027-2032) Table 13. IBS Treatment Industry Trends Table 14. IBS Treatment Industry Drivers Table 15. IBS Treatment Industry Opportunities and Challenges Table 16. IBS Treatment Industry Restraints Table 17. Global IBS Treatment Revenue by Company (US$ Million) & (2021-2026) Table 18. Global IBS Treatment Revenue Market Share by Company (2021-2026) Table 19. Global IBS Treatment Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global IBS Treatment Key Company Head Office and Area Served Table 21. Global IBS Treatment Company, Product Type & Application Table 22. Global IBS Treatment Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global IBS Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global IBS Treatment Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global IBS Treatment Market Size by Type (2021-2026) & (US$ Million) Table 27. Global IBS Treatment Market Size by Type (2027-2032) & (US$ Million) Table 28. Global IBS Treatment Revenue Market Share by Type (2021-2026) Table 29. Global IBS Treatment Revenue Market Share by Type (2027-2032) Table 30. Global IBS Treatment Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global IBS Treatment Market Size by Application (2021-2026) & (US$ Million) Table 32. Global IBS Treatment Market Size by Application (2027-2032) & (US$ Million) Table 33. Global IBS Treatment Revenue Market Share by Application (2021-2026) Table 34. Global IBS Treatment Revenue Market Share by Application (2027-2032) Table 35. Takeda Pharmaceutical Company (Japan) Company Information Table 36. Takeda Pharmaceutical Company (Japan) Business Overview Table 37. Takeda Pharmaceutical Company (Japan) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Takeda Pharmaceutical Company (Japan) IBS Treatment Product Portfolio Table 39. Takeda Pharmaceutical Company (Japan) Recent Development Table 40. Nestle (Switzerland) Company Information Table 41. Nestle (Switzerland) Business Overview Table 42. Nestle (Switzerland) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Nestle (Switzerland) IBS Treatment Product Portfolio Table 44. Nestle (Switzerland) Recent Development Table 45. Novartis (Switzerland) Company Information Table 46. Novartis (Switzerland) Business Overview Table 47. Novartis (Switzerland) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Novartis (Switzerland) IBS Treatment Product Portfolio Table 49. Novartis (Switzerland) Recent Development Table 50. Pfizer (U.S.) Company Information Table 51. Pfizer (U.S.) Business Overview Table 52. Pfizer (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Pfizer (U.S.) IBS Treatment Product Portfolio Table 54. Pfizer (U.S.) Recent Development Table 55. Synthetic Biologics (U.S.) Company Information Table 56. Synthetic Biologics (U.S.) Business Overview Table 57. Synthetic Biologics (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Synthetic Biologics (U.S.) IBS Treatment Product Portfolio Table 59. Synthetic Biologics (U.S.) Recent Development Table 60. Synergy Pharmaceuticals (U.S.) Company Information Table 61. Synergy Pharmaceuticals (U.S.) Business Overview Table 62. Synergy Pharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Synergy Pharmaceuticals (U.S.) IBS Treatment Product Portfolio Table 64. Synergy Pharmaceuticals (U.S.) Recent Development Table 65. Sucampo Pharmaceuticals (U.S.) Company Information Table 66. Sucampo Pharmaceuticals (U.S.) Business Overview Table 67. Sucampo Pharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Sucampo Pharmaceuticals (U.S.) IBS Treatment Product Portfolio Table 69. Sucampo Pharmaceuticals (U.S.) Recent Development Table 70. Sebela Pharmaceuticals (Ireland) Company Information Table 71. Sebela Pharmaceuticals (Ireland) Business Overview Table 72. Sebela Pharmaceuticals (Ireland) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Sebela Pharmaceuticals (Ireland) IBS Treatment Product Portfolio Table 74. Sebela Pharmaceuticals (Ireland) Recent Development Table 75. RedHill Biopharma (Israel) Company Information Table 76. RedHill Biopharma (Israel) Business Overview Table 77. RedHill Biopharma (Israel) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. RedHill Biopharma (Israel) IBS Treatment Product Portfolio Table 79. RedHill Biopharma (Israel) Recent Development Table 80. Protagonist Therapeutics (U.S.) Company Information Table 81. Protagonist Therapeutics (U.S.) Business Overview Table 82. Protagonist Therapeutics (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Protagonist Therapeutics (U.S.) IBS Treatment Product Portfolio Table 84. Protagonist Therapeutics (U.S.) Recent Development Table 85. Probi (Sweden) Company Information Table 86. Probi (Sweden) Business Overview Table 87. Probi (Sweden) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. Probi (Sweden) IBS Treatment Product Portfolio Table 89. Probi (Sweden) Recent Development Table 90. Lexicon Pharmaceuticals (U.S.) Company Information Table 91. Lexicon Pharmaceuticals (U.S.) Business Overview Table 92. Lexicon Pharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 93. Lexicon Pharmaceuticals (U.S.) IBS Treatment Product Portfolio Table 94. Lexicon Pharmaceuticals (U.S.) Recent Development Table 95. Ironwood Pharmaceuticals (U.S.) Company Information Table 96. Ironwood Pharmaceuticals (U.S.) Business Overview Table 97. Ironwood Pharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 98. Ironwood Pharmaceuticals (U.S.) IBS Treatment Product Portfolio Table 99. Ironwood Pharmaceuticals (U.S.) Recent Development Table 100. Ipsen (France) Company Information Table 101. Ipsen (France) Business Overview Table 102. Ipsen (France) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 103. Ipsen (France) IBS Treatment Product Portfolio Table 104. Ipsen (France) Recent Development Table 105. Innovate Biopharmaceuticals (U.S.) Company Information Table 106. Innovate Biopharmaceuticals (U.S.) Business Overview Table 107. Innovate Biopharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 108. Innovate Biopharmaceuticals (U.S.) IBS Treatment Product Portfolio Table 109. Innovate Biopharmaceuticals (U.S.) Recent Development Table 110. Bausch Health Company Information Table 111. Bausch Health Business Overview Table 112. Bausch Health IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 113. Bausch Health IBS Treatment Product Portfolio Table 114. Bausch Health Recent Development Table 115. AstraZeneca (U.K) Company Information Table 116. AstraZeneca (U.K) Business Overview Table 117. AstraZeneca (U.K) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 118. AstraZeneca (U.K) IBS Treatment Product Portfolio Table 119. AstraZeneca (U.K) Recent Development Table 120. Astellas Pharma (Japan) Company Information Table 121. Astellas Pharma (Japan) Business Overview Table 122. Astellas Pharma (Japan) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 123. Astellas Pharma (Japan) IBS Treatment Product Portfolio Table 124. Astellas Pharma (Japan) Recent Development Table 125. Ardelyx (U.S.) Company Information Table 126. Ardelyx (U.S.) Business Overview Table 127. Ardelyx (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 128. Ardelyx (U.S.) IBS Treatment Product Portfolio Table 129. Ardelyx (U.S.) Recent Development Table 130. Allergan (Ireland) Company Information Table 131. Allergan (Ireland) Business Overview Table 132. Allergan (Ireland) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 133. Allergan (Ireland) IBS Treatment Product Portfolio Table 134. Allergan (Ireland) Recent Development Table 135. Alfasigma USA (Italy) Company Information Table 136. Alfasigma USA (Italy) Business Overview Table 137. Alfasigma USA (Italy) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 138. Alfasigma USA (Italy) IBS Treatment Product Portfolio Table 139. Alfasigma USA (Italy) Recent Development Table 140. Abbott Laboratories (U.S.) Company Information Table 141. Abbott Laboratories (U.S.) Business Overview Table 142. Abbott Laboratories (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 143. Abbott Laboratories (U.S.) IBS Treatment Product Portfolio Table 144. Abbott Laboratories (U.S.) Recent Development Table 145. North America IBS Treatment Market Size by Type (2021-2026) & (US$ Million) Table 146. North America IBS Treatment Market Size by Type (2027-2032) & (US$ Million) Table 147. North America IBS Treatment Market Size by Application (2021-2026) & (US$ Million) Table 148. North America IBS Treatment Market Size by Application (2027-2032) & (US$ Million) Table 149. North America IBS Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 150. North America IBS Treatment Market Size by Country (2021-2026) Table 151. North America IBS Treatment Market Size by Country (2027-2032) Table 152. Europe IBS Treatment Market Size by Type (2021-2026) & (US$ Million) Table 153. Europe IBS Treatment Market Size by Type (2027-2032) & (US$ Million) Table 154. Europe IBS Treatment Market Size by Application (2021-2026) & (US$ Million) Table 155. Europe IBS Treatment Market Size by Application (2027-2032) & (US$ Million) Table 156. Europe IBS Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 157. Europe IBS Treatment Market Size by Country (2021-2026) Table 158. Europe IBS Treatment Market Size by Country (2027-2032) Table 159. China IBS Treatment Market Size by Type (2021-2026) & (US$ Million) Table 160. China IBS Treatment Market Size by Type (2027-2032) & (US$ Million) Table 161. China IBS Treatment Market Size by Application (2021-2026) & (US$ Million) Table 162. China IBS Treatment Market Size by Application (2027-2032) & (US$ Million) Table 163. Asia IBS Treatment Market Size by Type (2021-2026) & (US$ Million) Table 164. Asia IBS Treatment Market Size by Type (2027-2032) & (US$ Million) Table 165. Asia IBS Treatment Market Size by Application (2021-2026) & (US$ Million) Table 166. Asia IBS Treatment Market Size by Application (2027-2032) & (US$ Million) Table 167. Asia IBS Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 168. Asia IBS Treatment Market Size by Country (2021-2026) Table 169. Asia IBS Treatment Market Size by Country (2027-2032) Table 170. South America, Middle East & Africa IBS Treatment Market Size by Type (2021-2026) & (US$ Million) Table 171. South America, Middle East & Africa IBS Treatment Market Size by Type (2027-2032) & (US$ Million) Table 172. South America, Middle East & Africa IBS Treatment Market Size by Application (2021-2026) & (US$ Million) Table 173. South America, Middle East & Africa IBS Treatment Market Size by Application (2027-2032) & (US$ Million) Table 174. South America, Middle East & Africa IBS Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 175. South America, Middle East & Africa IBS Treatment Market Size by Country (2021-2026) Table 176. South America, Middle East & Africa IBS Treatment Market Size by Country (2027-2032) Table 177. Research Programs/Design for This Report Table 178. Authors List of This Report Table 179. Secondary Sources Table 180. Primary Sources List of Figures Figure 1. IBS Treatment Product Image Figure 2. Global IBS Treatment Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global IBS Treatment Market Share by Type: 2025 VS 2032 Figure 4. IBS-D Image Figure 5. IBS-C Image Figure 6. IBS-M Image Figure 7. Global IBS Treatment Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global IBS Treatment Market Share by Application: 2025 VS 2032 Figure 9. Hospitals Image Figure 10. Clinics Image Figure 11. Research Laboratories Image Figure 12. Global IBS Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 14. Global IBS Treatment Market Share by Region: 2025 VS 2032 Figure 15. Years Considered Figure 16. Global IBS Treatment Market Share by Players in 2025 Figure 17. Global Top 5 and 10 IBS Treatment Players Market Share by Revenue in 2025 Figure 18. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global IBS Treatment Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global IBS Treatment Revenue Market Share by Type (2021-2032) Figure 21. Global IBS Treatment Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global IBS Treatment Revenue Market Share by Application (2021-2032) Figure 23. North America IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 24. North America IBS Treatment Market Share by Type (2021-2032) Figure 25. North America IBS Treatment Market Share by Application (2021-2032) Figure 26. North America IBS Treatment Market Share by Country (2021-2032) Figure 27. United States IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 28. Canada IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 29. Mexico IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 30. Europe IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 31. Europe IBS Treatment Market Share by Type (2021-2032) Figure 32. Europe IBS Treatment Market Share by Application (2021-2032) Figure 33. Europe IBS Treatment Market Share by Country (2021-2032) Figure 34. Germany IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 35. France IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 36. U.K. IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 37. Italy IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 38. Russia IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 39. Nordic Countries IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 40. China IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 41. China IBS Treatment Market Share by Type (2021-2032) Figure 42. China IBS Treatment Market Share by Application (2021-2032) Figure 43. Asia IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 44. Asia IBS Treatment Market Share by Type (2021-2032) Figure 45. Asia IBS Treatment Market Share by Application (2021-2032) Figure 46. Asia IBS Treatment Market Share by Country (2021-2032) Figure 47. Japan IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 48. South Korea IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 49. Taiwan IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 50. Southeast Asia IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 51. India IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 52. Australia IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa IBS Treatment Market Share by Type (2021-2032) Figure 55. South America, Middle East & Africa IBS Treatment Market Share by Application (2021-2032) Figure 56. South America, Middle East & Africa IBS Treatment Market Share by Country (2021-2032) Figure 57. Brazil IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 58. South Africa IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 59. Saudi Arabia IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 60. Turkey IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 61. Argentina IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 62. UAE IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 63. Egypt IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 64. Chile IBS Treatment Market Size (2021-2032) & (US$ Million) Figure 65. Research Process Figure 66. Key Executives Interviewed

Scope & coverage.

Types
  • IBS-D
  • IBS-C
  • IBS-M
Applications
  • Hospitals
  • Clinics
  • Research Laboratories
Companies covered
  • Takeda Pharmaceutical Company (Japan)
  • Nestle (Switzerland)
  • Novartis (Switzerland)
  • Pfizer (U.S.)
  • Synthetic Biologics (U.S.)
  • Synergy Pharmaceuticals (U.S.)
  • Sucampo Pharmaceuticals (U.S.)
  • Sebela Pharmaceuticals (Ireland)
  • RedHill Biopharma (Israel)
  • Protagonist Therapeutics (U.S.)
  • Probi (Sweden)
  • Lexicon Pharmaceuticals (U.S.)
  • Ironwood Pharmaceuticals (U.S.)
  • Ipsen (France)
  • Innovate Biopharmaceuticals (U.S.)
  • Bausch Health
  • AstraZeneca (U.K)
  • Astellas Pharma (Japan)
  • Ardelyx (U.S.)
  • Allergan (Ireland)
  • Alfasigma USA (Italy)
  • Abbott Laboratories (U.S.)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global IBS Treatment Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 IBS-D
  5. 1.2.3 IBS-C
  6. 1.2.4 IBS-M
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global IBS Treatment Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Hospitals
  10. 1.3.3 Clinics
  11. 1.3.4 Research Laboratories
  12. 1.4 Global Market Growth Prospects
  13. 1.5 Global IBS Treatment Growth Trends by Region
  14. 1.5.1 Global IBS Treatment Market Size by Region: 2021 VS 2025 VS 2032
  15. 1.5.2 IBS Treatment Market Size by Region (2021-2026)
  16. 1.5.3 IBS Treatment Market Size by Region (2027-2032)
  17. 1.6 Assumptions and Limitations
  18. 1.7 Study Goals and Objectives
  19. 1.8 Years Considered
2 Global IBS Treatment Market Dynamics
  1. 2.1 IBS Treatment Industry Trends
  2. 2.2 IBS Treatment Industry Drivers
  3. 2.3 IBS Treatment Industry Opportunities and Challenges
  4. 2.4 IBS Treatment Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global IBS Treatment Revenue by Company (2021-2026)
  2. 3.2 Global IBS Treatment Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global IBS Treatment Key Company Head office and Area Served
  4. 3.4 Global IBS Treatment Company, Product Type & Application
  5. 3.5 Global IBS Treatment Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global IBS Treatment Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 IBS Treatment Players Market Share by Revenue in 2025
  9. 3.6.3 2025 IBS Treatment Tier 1, Tier 2, and Tier 3
4 IBS Treatment Market by Type
  1. 4.1 Global IBS Treatment Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global IBS Treatment Market Size by Type (2021-2032)
  3. 4.3 Global IBS Treatment Market Size Share by Type (2021-2032)
5 IBS Treatment Market by Application
  1. 5.1 Global IBS Treatment Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global IBS Treatment Market Size by Application (2021-2032)
  3. 5.3 Global IBS Treatment Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Takeda Pharmaceutical Company (Japan)
  2. 6.1.1 Takeda Pharmaceutical Company (Japan) Company Information
  3. 6.1.2 Takeda Pharmaceutical Company (Japan) Business Overview
  4. 6.1.3 Takeda Pharmaceutical Company (Japan) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Takeda Pharmaceutical Company (Japan) IBS Treatment Product Portfolio
  6. 6.1.5 Takeda Pharmaceutical Company (Japan) Recent Developments
  7. 6.2 Nestle (Switzerland)
  8. 6.2.1 Nestle (Switzerland) Company Information
  9. 6.2.2 Nestle (Switzerland) Business Overview
  10. 6.2.3 Nestle (Switzerland) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Nestle (Switzerland) IBS Treatment Product Portfolio
  12. 6.2.5 Nestle (Switzerland) Recent Developments
  13. 6.3 Novartis (Switzerland)
  14. 6.3.1 Novartis (Switzerland) Company Information
  15. 6.3.2 Novartis (Switzerland) Business Overview
  16. 6.3.3 Novartis (Switzerland) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Novartis (Switzerland) IBS Treatment Product Portfolio
  18. 6.3.5 Novartis (Switzerland) Recent Developments
  19. 6.4 Pfizer (U.S.)
  20. 6.4.1 Pfizer (U.S.) Company Information
  21. 6.4.2 Pfizer (U.S.) Business Overview
  22. 6.4.3 Pfizer (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Pfizer (U.S.) IBS Treatment Product Portfolio
  24. 6.4.5 Pfizer (U.S.) Recent Developments
  25. 6.5 Synthetic Biologics (U.S.)
  26. 6.5.1 Synthetic Biologics (U.S.) Company Information
  27. 6.5.2 Synthetic Biologics (U.S.) Business Overview
  28. 6.5.3 Synthetic Biologics (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Synthetic Biologics (U.S.) IBS Treatment Product Portfolio
  30. 6.5.5 Synthetic Biologics (U.S.) Recent Developments
  31. 6.6 Synergy Pharmaceuticals (U.S.)
  32. 6.6.1 Synergy Pharmaceuticals (U.S.) Company Information
  33. 6.6.2 Synergy Pharmaceuticals (U.S.) Business Overview
  34. 6.6.3 Synergy Pharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Synergy Pharmaceuticals (U.S.) IBS Treatment Product Portfolio
  36. 6.6.5 Synergy Pharmaceuticals (U.S.) Recent Developments
  37. 6.7 Sucampo Pharmaceuticals (U.S.)
  38. 6.7.1 Sucampo Pharmaceuticals (U.S.) Company Information
  39. 6.7.2 Sucampo Pharmaceuticals (U.S.) Business Overview
  40. 6.7.3 Sucampo Pharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Sucampo Pharmaceuticals (U.S.) IBS Treatment Product Portfolio
  42. 6.7.5 Sucampo Pharmaceuticals (U.S.) Recent Developments
  43. 6.8 Sebela Pharmaceuticals (Ireland)
  44. 6.8.1 Sebela Pharmaceuticals (Ireland) Company Information
  45. 6.8.2 Sebela Pharmaceuticals (Ireland) Business Overview
  46. 6.8.3 Sebela Pharmaceuticals (Ireland) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Sebela Pharmaceuticals (Ireland) IBS Treatment Product Portfolio
  48. 6.8.5 Sebela Pharmaceuticals (Ireland) Recent Developments
  49. 6.9 RedHill Biopharma (Israel)
  50. 6.9.1 RedHill Biopharma (Israel) Company Information
  51. 6.9.2 RedHill Biopharma (Israel) Business Overview
  52. 6.9.3 RedHill Biopharma (Israel) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 RedHill Biopharma (Israel) IBS Treatment Product Portfolio
  54. 6.9.5 RedHill Biopharma (Israel) Recent Developments
  55. 6.10 Protagonist Therapeutics (U.S.)
  56. 6.10.1 Protagonist Therapeutics (U.S.) Company Information
  57. 6.10.2 Protagonist Therapeutics (U.S.) Business Overview
  58. 6.10.3 Protagonist Therapeutics (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Protagonist Therapeutics (U.S.) IBS Treatment Product Portfolio
  60. 6.10.5 Protagonist Therapeutics (U.S.) Recent Developments
  61. 6.11 Probi (Sweden)
  62. 6.11.1 Probi (Sweden) Company Information
  63. 6.11.2 Probi (Sweden) Business Overview
  64. 6.11.3 Probi (Sweden) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Probi (Sweden) IBS Treatment Product Portfolio
  66. 6.11.5 Probi (Sweden) Recent Developments
  67. 6.12 Lexicon Pharmaceuticals (U.S.)
  68. 6.12.1 Lexicon Pharmaceuticals (U.S.) Company Information
  69. 6.12.2 Lexicon Pharmaceuticals (U.S.) Business Overview
  70. 6.12.3 Lexicon Pharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Lexicon Pharmaceuticals (U.S.) IBS Treatment Product Portfolio
  72. 6.12.5 Lexicon Pharmaceuticals (U.S.) Recent Developments
  73. 6.13 Ironwood Pharmaceuticals (U.S.)
  74. 6.13.1 Ironwood Pharmaceuticals (U.S.) Company Information
  75. 6.13.2 Ironwood Pharmaceuticals (U.S.) Business Overview
  76. 6.13.3 Ironwood Pharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Ironwood Pharmaceuticals (U.S.) IBS Treatment Product Portfolio
  78. 6.13.5 Ironwood Pharmaceuticals (U.S.) Recent Developments
  79. 6.14 Ipsen (France)
  80. 6.14.1 Ipsen (France) Company Information
  81. 6.14.2 Ipsen (France) Business Overview
  82. 6.14.3 Ipsen (France) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Ipsen (France) IBS Treatment Product Portfolio
  84. 6.14.5 Ipsen (France) Recent Developments
  85. 6.15 Innovate Biopharmaceuticals (U.S.)
  86. 6.15.1 Innovate Biopharmaceuticals (U.S.) Company Information
  87. 6.15.2 Innovate Biopharmaceuticals (U.S.) Business Overview
  88. 6.15.3 Innovate Biopharmaceuticals (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Innovate Biopharmaceuticals (U.S.) IBS Treatment Product Portfolio
  90. 6.15.5 Innovate Biopharmaceuticals (U.S.) Recent Developments
  91. 6.16 Bausch Health
  92. 6.16.1 Bausch Health Company Information
  93. 6.16.2 Bausch Health Business Overview
  94. 6.16.3 Bausch Health IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Bausch Health IBS Treatment Product Portfolio
  96. 6.16.5 Bausch Health Recent Developments
  97. 6.17 AstraZeneca (U.K)
  98. 6.17.1 AstraZeneca (U.K) Company Information
  99. 6.17.2 AstraZeneca (U.K) Business Overview
  100. 6.17.3 AstraZeneca (U.K) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 AstraZeneca (U.K) IBS Treatment Product Portfolio
  102. 6.17.5 AstraZeneca (U.K) Recent Developments
  103. 6.18 Astellas Pharma (Japan)
  104. 6.18.1 Astellas Pharma (Japan) Company Information
  105. 6.18.2 Astellas Pharma (Japan) Business Overview
  106. 6.18.3 Astellas Pharma (Japan) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Astellas Pharma (Japan) IBS Treatment Product Portfolio
  108. 6.18.5 Astellas Pharma (Japan) Recent Developments
  109. 6.19 Ardelyx (U.S.)
  110. 6.19.1 Ardelyx (U.S.) Company Information
  111. 6.19.2 Ardelyx (U.S.) Business Overview
  112. 6.19.3 Ardelyx (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  113. 6.19.4 Ardelyx (U.S.) IBS Treatment Product Portfolio
  114. 6.19.5 Ardelyx (U.S.) Recent Developments
  115. 6.20 Allergan (Ireland)
  116. 6.20.1 Allergan (Ireland) Company Information
  117. 6.20.2 Allergan (Ireland) Business Overview
  118. 6.20.3 Allergan (Ireland) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  119. 6.20.4 Allergan (Ireland) IBS Treatment Product Portfolio
  120. 6.20.5 Allergan (Ireland) Recent Developments
  121. 6.21 Alfasigma USA (Italy)
  122. 6.21.1 Alfasigma USA (Italy) Company Information
  123. 6.21.2 Alfasigma USA (Italy) Business Overview
  124. 6.21.3 Alfasigma USA (Italy) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  125. 6.21.4 Alfasigma USA (Italy) IBS Treatment Product Portfolio
  126. 6.21.5 Alfasigma USA (Italy) Recent Developments
  127. 6.22 Abbott Laboratories (U.S.)
  128. 6.22.1 Abbott Laboratories (U.S.) Company Information
  129. 6.22.2 Abbott Laboratories (U.S.) Business Overview
  130. 6.22.3 Abbott Laboratories (U.S.) IBS Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  131. 6.22.4 Abbott Laboratories (U.S.) IBS Treatment Product Portfolio
  132. 6.22.5 Abbott Laboratories (U.S.) Recent Developments
7 North America
  1. 7.1 North America IBS Treatment Market Size (2021-2032)
  2. 7.2 North America IBS Treatment Market Size by Type
  3. 7.2.1 North America IBS Treatment Market Size by Type (2021-2026)
  4. 7.2.2 North America IBS Treatment Market Size by Type (2027-2032)
  5. 7.2.3 North America IBS Treatment Market Share by Type (2021-2032)
  6. 7.3 North America IBS Treatment Market Size by Application
  7. 7.3.1 North America IBS Treatment Market Size by Application (2021-2026)
  8. 7.3.2 North America IBS Treatment Market Size by Application (2027-2032)
  9. 7.3.3 North America IBS Treatment Market Share by Application (2021-2032)
  10. 7.4 North America IBS Treatment Market Size by Country
  11. 7.4.1 North America IBS Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America IBS Treatment Market Size by Country (2021-2026)
  13. 7.4.3 North America IBS Treatment Market Size by Country (2027-2032)
  14. 7.4.4 North America IBS Treatment Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe IBS Treatment Market Size (2021-2032)
  2. 8.2 Europe IBS Treatment Market Size by Type
  3. 8.2.1 Europe IBS Treatment Market Size by Type (2021-2026)
  4. 8.2.2 Europe IBS Treatment Market Size by Type (2027-2032)
  5. 8.2.3 Europe IBS Treatment Market Share by Type (2021-2032)
  6. 8.3 Europe IBS Treatment Market Size by Application
  7. 8.3.1 Europe IBS Treatment Market Size by Application (2021-2026)
  8. 8.3.2 Europe IBS Treatment Market Size by Application (2027-2032)
  9. 8.3.3 Europe IBS Treatment Market Share by Application (2021-2032)
  10. 8.4 Europe IBS Treatment Market Size by Country
  11. 8.4.1 Europe IBS Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe IBS Treatment Market Size by Country (2021-2026)
  13. 8.4.3 Europe IBS Treatment Market Size by Country (2027-2032)
  14. 8.4.4 Europe IBS Treatment Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China IBS Treatment Market Size (2021-2032)
  2. 9.2 China IBS Treatment Market Size by Type
  3. 9.2.1 China IBS Treatment Market Size by Type (2021-2026)
  4. 9.2.2 China IBS Treatment Market Size by Type (2027-2032)
  5. 9.2.3 China IBS Treatment Market Share by Type (2021-2032)
  6. 9.3 China IBS Treatment Market Size by Application
  7. 9.3.1 China IBS Treatment Market Size by Application (2021-2026)
  8. 9.3.2 China IBS Treatment Market Size by Application (2027-2032)
  9. 9.3.3 China IBS Treatment Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia IBS Treatment Market Size (2021-2032)
  2. 10.2 Asia IBS Treatment Market Size by Type
  3. 10.2.1 Asia IBS Treatment Market Size by Type (2021-2026)
  4. 10.2.2 Asia IBS Treatment Market Size by Type (2027-2032)
  5. 10.2.3 Asia IBS Treatment Market Share by Type (2021-2032)
  6. 10.3 Asia IBS Treatment Market Size by Application
  7. 10.3.1 Asia IBS Treatment Market Size by Application (2021-2026)
  8. 10.3.2 Asia IBS Treatment Market Size by Application (2027-2032)
  9. 10.3.3 Asia IBS Treatment Market Share by Application (2021-2032)
  10. 10.4 Asia IBS Treatment Market Size by Country
  11. 10.4.1 Asia IBS Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia IBS Treatment Market Size by Country (2021-2026)
  13. 10.4.3 Asia IBS Treatment Market Size by Country (2027-2032)
  14. 10.4.4 Asia IBS Treatment Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa IBS Treatment Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa IBS Treatment Market Size by Type
  3. 11.2.1 South America, Middle East & Africa IBS Treatment Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa IBS Treatment Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa IBS Treatment Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa IBS Treatment Market Size by Application
  7. 11.3.1 South America, Middle East & Africa IBS Treatment Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa IBS Treatment Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa IBS Treatment Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa IBS Treatment Market Size by Country
  11. 11.4.1 South America, Middle East & Africa IBS Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa IBS Treatment Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa IBS Treatment Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa IBS Treatment Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst